Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma

Roberta Rosa Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica; Università di Napoli “Federico II”; Naples, Italy

Vincenzo Damiano Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica; Università di Napoli “Federico II”; Naples, Italy

Luigi Formisano Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica; Università di Napoli “Federico II”; Naples, Italy

Lucia Nappi Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica; Università di Napoli “Federico II”; Naples, Italy

Roberta Marciano Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica; Università di Napoli “Federico II”; Naples, Italy

Bianca Maria Veneziani Dipartimento di Biologia e Patologia Cellulare e Molecolare “L. Califano”; Università di Napoli “Federico II”; Naples, Italy

Sabino De Placido Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica; Università di Napoli “Federico II”; Naples, Italy

Roberto Bianco Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica; Università di Napoli “Federico II”; Naples, ItalyCorrespondence[email protected]

show all

Abstract

The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical trials investigating the combination of mTOR inhibitors with TLR9 agonists in RCC patients have been performed to date. Our results may pave the way to translate this combinatorial approach to the clinical setting.

Keywords: :

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma

Information for

Open access

Opportunities

Help and information

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma

Abstract

Disclosure of Potential Conflicts of Interest

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature